Early transplantation of mesenchymal stem cells after spinal cord injury relieves pain hypersensitivity through suppression of pain-related signaling cascades and reduced inflammatory cell recruitment by Watanabe, Shuji et al.
Early Transplantation of Mesenchymal
Stem Cells After Spinal Cord Injury Relieves
Pain Hypersensitivity Through Suppression of
Pain-Related Signaling Cascades and Reduced
Inflammatory Cell Recruitment
SHUJI WATANABE,a KENZO UCHIDA,a HIDEAKI NAKAJIMA,a HIDEAKI MATSUO,a DAISUKE SUGITA,a
AI YOSHIDA,a KAZUYA HONJOH,a WILLIAM E.B. JOHNSON,b HISATOSHI BABAa
Key Words. Spinal cord injury • Bone marrow-derived mesenchymal stem cells • Transplantation •
Central neuropathic pain • Mitogen-activated protein kinase (MAPK) pathway • Hema-
togenous macrophages • Resident microglia • Blood-spinal cord barrier
ABSTRACT
Bone marrow-derived mesenchymal stem cells (BMSC) modulate inﬂammatory/immune
responses and promote motor functional recovery after spinal cord injury (SCI). However, the
effects of BMSC transplantation on central neuropathic pain and neuronal hyperexcitability after
SCI remain elusive. This is of importance because BMSC-based therapies have been proposed
for clinical treatment. We investigated the effects of BMSC transplantation on pain hypersensi-
tivity in green ﬂuorescent protein (GFP)-positive bone marrow-chimeric mice subjected to a con-
tusion SCI, and the mechanisms of such effects. BMSC transplantation at day 3 post-SCI
improved motor function and relieved SCI-induced hypersensitivities to mechanical and thermal
stimulation. The pain improvements were mediated by suppression of protein kinase C-c and
phosphocyclic AMP response element binding protein expression in dorsal horn neurons. BMSC
transplants signiﬁcantly reduced levels of p-p38 mitogen-activated protein kinase and extracellu-
lar signal-regulated kinase (p-ERK1/2) in both hematogenous macrophages and resident micro-
glia and signiﬁcantly reduced the inﬁltration of CD11b and GFP double-positive hematogenous
macrophages without decreasing the CD11b-positive and GFP-negative activated spinal-microglia
population. BMSC transplants prevented hematogenous macrophages recruitment by restoration
of the blood-spinal cord barrier (BSCB), which was associated with decreased levels of (a)
inﬂammatory cytokines (tumor necrosis factor-a, interleukin-6); (b) mediators of early secondary
vascular pathogenesis (matrix metallopeptidase 9); (c) macrophage recruiting factors (CCL2,
CCL5, and CXCL10), but increased levels of a microglial stimulating factor (granulocyte–macro-
phage colony-stimulating factor). These ﬁndings support the use of BMSC transplants for SCI
treatment. Furthermore, they suggest that BMSC reduce neuropathic pain through a variety of
related mechanisms that include neuronal sparing and restoration of the disturbed BSCB, medi-
ated through modulation of the activity of spinal-resident microglia and the activity and recruit-
ment of hematogenous macrophages. STEM CELLS 2015;33:1902–1914
INTRODUCTION
Spinal cord injury (SCI) not only results in loss
of normal sensation, but often debilitating
neuropathic pain. Up to 80% of patients with
SCI develop chronic neuropathic pain, which
can be localized below, girdling, or above the
level of the SCI lesion [1–4]. Beneﬁcial effects
of cell transplantation therapy in sensory
recovery and reduced pain after SCI have been
reported [5, 6]; however, other studies
described harmful effects of cell transplants [7,
8]. Research has shown that autologous bone
marrow-derived mesenchymal stem cell
(BMSC) transplants increase sensory function
after contusion SCI, but the effects of BMSC
on SCI-induced chronic neuropathic pain
remain contentious [9–12]. This is problematic
because BMSC transplants for SCI treatments
are being developed for clinical applications
[13–15].
Neuropathic pain following SCI is associ-
ated with a number of molecular and cellular
events. SCI results in a marked increase in
extracellular concentrations of glutamate fol-
lowed by activation of excitatory amino acid
receptors and ion channels [16] with subse-
quent activation of intracellular downstream
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TRANSLATIONAL AND CLINICAL
RESEARCH
pathways that result in altered gene expression. These events
are sufﬁcient to produce persistent neuronal hyperexcitability
of spinal dorsal horn neurons or central neuropathic pain
[17]. The mechanism of neuropathic pain after SCI involves
the activation of members of the mitogen-activated protein
kinase (MAPK) family, in particular, p38 MAPK, extracellular
signal-regulated kinase (ERK) including ERK1/2, and c-Jun N-
terminal kinase (JNK) [18]. Experimental models of peripheral
neuropathic pain have also highlighted the roles of MAPK in
neuronal hyperexcitability and demonstrated the selective
expression of MAPK in activated microglia present in the spi-
nal cord dorsal horn [19, 20]. Following thoracic SCI, both p38
MAPK and ERK are activated in spinal microglia, which con-
tributes to neuronal hyperexcitability and central neuropathic
pain [17, 21–23]. Furthermore, inhibition of microglial activa-
tion by minocycline (an anti-inﬂammatory drug) was reported
to reduce SCI-induced pain below the injury site by attenuat-
ing p38 MAPK and ERK activation in microglia [23, 24].
Although activated microglia are thought to contribute to
neuropathic pain symptoms through their release of modula-
tors of neuronal excitability [25], these data derive largely
from analyses of resident cells at sites remote and caudal to
thoracic lesions [22, 26, 27]. However, following thoracic SCI
the blood-spinal cord barrier (BSCB) is often disrupted and an
inﬂux of blood-borne inﬂammatory and other immune cells
contribute to an intensive inﬂammatory response localized
around the injured site [28]. Inﬁltrating macrophages have
both detrimental [29, 30] and beneﬁcial roles [31, 32] in spi-
nal repair, although the net effect of their activity is unclear.
In addition, it is not well-known how activated resident micro-
glia and macrophages of different origins contribute to post-
SCI dorsal horn hyperexcitability and central neuropathic pain,
particularly at the level of the lesion. One reason for the difﬁ-
culty in differentiating microglia from inﬁltrating monocytes/
macrophages relates to their morphological and phenotypic
similarities [33]. However, in response to peripheral nerve
injury, there is increasing evidence that inﬁltration of periph-
eral immune cells, including macrophages, into the spinal
cord contributes to the pathogenesis of neuropathic pain [34,
35]. Understanding the contribution of each cell type, that is,
of inﬂammatory cells of hematogenous monocytic lineage ver-
sus resident microglia to SCI-induced neuropathic pain is
important to direct the search for novel therapies, especially
involving BMSC transplants as these are known to inﬂuence
macrophage activity.
In this study, we investigated the effects of BMSC trans-
plantation on post-SCI chronic neuropathic pain. Speciﬁcally,
we focused on the effects of BMSC transplants on microglia
and macrophages and MAPK signalling at the level of the
lesion. Furthermore, we used chimeric mice wherein the bone
marrow contained hematogenous cells that expressed green
ﬂuorescent protein (GFP). This was to determine the differen-
tial effects of transplanted BMSC on spinal-resident microglia
and bone marrow-derived macrophages.
MATERIALS AND METHODS
Experimental Animals
All experiments followed the guidelines for the study of pain
in awake animals established by the International Association
for the Study of Pain [36]. Experiments were conducted in
453 adult male C57BL/6N mice (Nihon SLC, Shizuoka, Japan;
http://www.jslc.co.jp/), aged 10–12 weeks, with a mean body
weight of 27.56 0.82 g (6SD), and 20 adult male mice in
which enhanced GFP (EGFP) expression was driven by the
cytomegalovirus early enhancer b-actin (CAG) transgene (CAG-
EGFP mice; Nihon SLC, Shizuoka, Japan), aged 6–8 weeks,
with a mean body weight of 19.46 0.47 g (6 SD). The experi-
mental protocol was approved by the Ethics Committee for
Animal Experimentation of Fukui University.
The Contusion SCI Model
Each mouse was anesthetized before surgery with isoﬂurane
(Forane; Abbot, Tokyo, Japan; http://www.abbott.co.jp/), and
the spinal cord was exposed by laminectomy at the T9-T10
vertebral level using a surgical microscope (VANOX-S; Olympus
Optical, Tokyo, Japan; http://www.olympus.co.jp). A contusion
SCI was produced using the Inﬁnite Horizon Impactor (Preci-
sion Systems and Instrumentation LLC, Fairfax, VA; http://
www.presysin.com/) with an impact force of 60 kilodynes
(kdyn) [37]. In a sham SCI operation group, each mouse
underwent a laminectomy only at the T9-T10 vertebral level,
with no SCI performed.
Preparation of Bone Marrow-Derived Mesenchymal
Stem Cells
BMSC were isolated and cultured from the bone marrow of the
femur and tibia bones collected from young adult male C57BL/
6N or CAG-EGFP transgenic mice. The prepared bone marrow
cells were placed into dishes with Dulbecco’s modiﬁed Eagle’s
medium (DMEM; GIBCO, Grand Island, NY) supplemented with
10% fetal bovine serum (FBS; GIBCO; http://www.lifetechnolo-
gies.com/). Dissociated BMSC were isolated according to prefer-
ential adherence to tissue culture plastic as described in
Supporting Information Methods. Before all experiments using
BMSC transplants, ﬂow cytometric analysis conﬁrmed that
these cells were phenotypically BMSC based on positive immu-
nostaining for CD44, CD90, and CD29 and negative immuno-
staining for CD45 and CD11b (Supporting Information Fig. 1).
BMSC Transplantation
We divided animals into four groups according to the time of
transplantation of BMSCs that were isolated from C57BL/6N
mice. The BMSC transplantation was performed on days 1, 3, 7,
and 14 post-SCI. The treatment group received 2.0 3 105 BMSC
in 3 ll of DMEM, which were injected into the middle of the
contusion site, identiﬁed as the middle point of the laminec-
tomy area (identiﬁed by a hematoma at day 3) [38]. To maxi-
mize engraftment of all injected BMSC into the spinal cord, the
needle was not disconnected from the spinal cord for 5 minutes
after the injection. Control mice were injected with 3 ll of
DMEM alone (i.e., no cells) at each time point post-SCI. Sham-
operated mice were not injected with cells or with DMEM.
Assessment of Transplanted BMSC Survival
The relationship between the survival rates of transplanted
BMSCs with the time after SCI that the BMSCs were trans-
planted was initially assessed. The transplantation for these
survival studies were at 1, 3, 7, and 14 days post-injury. GFP-
positive BMSC survival was examined at 15 minutes, 1, 3, 7,
14, and 28 days after transplantation with 2.0 3 105 BMSCs in
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3 ll of culture medium. To assess BMSC survival, we examined
midsagittal sections prepared from the injured portion of the
spinal cord. The numbers of GFP-positive BMSCs in these sec-
tions were counted at each time point as described in the sec-
tion on semi-quantitative analysis of tissue staining. These data
have been expressed as the survival rate (%) of BMSCs at each
time point indicated compared with the number of GFP-
positive BMSCs present at 15 minutes after transplantation.
Bone Marrow-Chimeric Mice
We generated bone marrow-chimeric mice using highly puriﬁed,
genetically marked bone marrow cells as reported previously
[34, 39], enabling us to limit our studies to hematopoietic line-
ages. Isolated unfractionated marrow cells (5.0 3 106 cells)
from donor CAG-EGFP transgenic mice were injected intrave-
nously into the tail vein of a recipient mouse that had been
irradiated at 9.0 Gy for 30 minutes (4.5 Gy/15 minutes twice)
after covering the head with a lead plate. Their successful
engraftment and induction of chimerism was conﬁrmed after 4
weeks by Dual-laser Fluorescence-Activated Cell Sorting (FACS)
Calibur (BD Biosciences, San Jose, CA; http://www.bdbioscien-
ces.com/) analysis of recipient peripheral blood to identify
donor GFP1-bone marrow-derived cells. Bone marrow chimeric
mice were used for SCI surgery at the age of 10–12 weeks.
Behavioral and Sensory Testing
The Basso Mouse Locomotor Scale (BMS) is a 0 to 9-point
scale, which was developed to describe recovery of locomotor
function in mice after thoracic spinal cord contusion or trans-
ection injury [40]. BMS scores were recorded at times indi-
cated post-SCI for the left and right hind limbs, and averaged
to obtain a single calculated value per mouse per test.
Mechanical allodynia and thermal sensitivity were
recorded at times indicated post-SCI by two independent
examiners blinded to the experimental conditions. Mechanical
allodynia was assessed using the Dynamic Plantar Aesthesiom-
eter (Ugo Basile, Comerio, Italy; http://www.ugobasile.com/)
[41]. The withdrawal threshold (expressed in grams) was
measured ﬁve times and the reported value represents the
mean of these ﬁve evaluations. Thermal sensitivity of the
plantar hindpaws was tested according to the method
described previously [42] (Plantar Test Apparatus, Ugo Basile)
(Supporting Information Methods). Latency (in seconds) to
withdrawal from the heat source was recorded, together with
any other behavior indicating attendance to the stimulus,
including snifﬁng, licking, looking at the affected paw, or
attacking the stimulus. High and low latencies were dropped
for each paw, and the remaining six latencies were averaged
for each mouse [43].
We used the same technique to transplant 2.0 3 105
BMSCs in 3 ll DMEM versus 3 ll DMEM alone (as con-
trols) at day 3 post-SCI for detailed analysis of biochemistry
related to pain hypersensitivity. Previous reports indicate
that allodynia is present in approximately 81% of experi-
mental mouse models after SCI [44] and approximately 75%
of experimental rat models after contusion SCI [45]. For
this study, 142 mice underwent contusion SCI and were
examined using sensory tests for the presence of allodynia
and 111 (78.2%) of these were selected based on the pres-
ence of signiﬁcant sensory differences when compared with
the sham-operated group.
Immunohistochemistry
Perfused segments of the spinal cord obtained from separate
animals were embedded in optimal cutting temperature com-
pound (Sakura Finetek, Torrance, CA; http://www.sakura-ﬁne-
tek.com/) and cut on a cryostat for the preparation and
analysis of axial sections (for assessment of dorsal horn and
gray matter after SCI) or sagittal sections (for assessment of
the distribution of transplanted BMSCs and blood-derived
cells). All frozen sections were 20 lm thick and serially
mounted on glass slides (Supporting Information Methods).
All digitized images of immunopositivity were obtained using
a ﬂuorescence microscope (Olympus AX80; Olympus Optical)
or a confocal laser scanning microscope (model TCS SP2; Leica
Instruments, Nussloch, Germany; http://www.leica.com/).
Semi-Quantitative Analysis of Tissue Staining
For semiquantitative analysis of dorsal horn neuronal hyperexcit-
ability, 10 axial sections randomly selected at a distance up to
2 mm rostral and caudal to the site of the lesion were immuno-
stained with antibodies speciﬁc for putative markers, that is, for
protein kinase C-c (PKC-c) or phosphocyclic AMP response element
binding protein (p-CREB), both of which are upregulated in associa-
tion with at-level allodynia after contusion SCI [21, 27]. For PKC-c
staining in the superﬁcial laminae I-III of spinal dorsal horn, the
area and density of pixels within the threshold value representing
immunoreactivity were calculated. The extent of immunopositivity
for each antibody was calculated from the product of pixel density
and image area, which was determined using the color image ana-
lyzer (MacSCOPE; Mitani, Fukui, Japan; http://mitani-visual.jp/). For
p-CREB staining, the numbers of p-CREB- and neuronal nuclei
(NeuN)-double-positive cells in the superﬁcial laminae I-III of the
spinal dorsal horn were counted, as reported previously [46].
The number of GFP-positive BMSCs, CD11b- and GFP-
positive cells, CD11b-positive and GFP-negative cells, and p-38
MAPK and p-ERK1/2 colocalized with GFP positive cells were
counted. For this analysis, three mid-sagittal sections through
the injured portion of the spinal cord were randomly selected
and 20 high magniﬁcation (4003) nonoverlapping digitized
images were captured using a confocal microscope (TCS SP2)
within a region that was 2 mm rostral and caudal to the site
of lesion. Quantiﬁcation of cells in each image was performed
by MacSCOPE as described previously [47].
We assessed BSCB function at days 4, 7, and 14 post-SCI,
because we previously observed that the inﬁltration of blood-
derived macrophages peaked between 1 and 2 weeks after
SCI. BSCB was assessed as follows; 10 axial sections were ran-
domly selected at a distance up to 2 mm rostral and caudal to
the site of lesion and stained for albumin or immunolabeled
for platelet-derived growth factor receptor a (PDGFR-a). Digi-
tized images of the stained sections were collected and Mac-
SCOPE was used to calculate the relative intensity of albumin-
and PDGFR-a-positive signal intensity in the gray matter. The
mean pixel density of positivity was expressed as a percentage
of that for the total ﬁelds analyzed (pixel area/total ﬁeld) [48].
Flow Cytometric Analysis
At day 14 post-SCI, the damaged area of the spinal cord
(2.5 mm either side of the lesion) was surgically dissected for
ﬂow cytometry, as described previously [49] (Supporting
Information Methods). GFPpositive/CD45high/ CD11bhigh/GR-1negative
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cells were designated hematogenous macrophages and GFPnega-
tive/CD45high/ CD11bhigh/GR-1negative cells were designated endog-
enous activated microglia [49]. For intracellular staining [50],
these cells were resuspended in ﬁxation buffer (Santa Cruz Bio-
technology, Santa Cruz, CA; http://www.scbt.com/) and treated
with permeabilization buffer (Santa Cruz Biotechnology), fol-
lowed by resuspension in ice-cold phosphate-buffered saline and
incubation for 1 hour with rabbit phycoerythrin (1:200, Santa
Cruz Biotechnology) conjugated rabbit anti-p-p38 MAPK antibody
(1:200, Cell Signaling Technology, Danvers, MA; http://www.cell-
signal.com/) or rabbit anti-p-ERK1/2 antibody (1:200, Cell Signal-
ing Technology). Flow cytometry was performed immediately
using a FACS CantoTM II (BD Biosciences) using forward scatter
to further eliminate any cellular debris from analysis.
Immunoblot Analysis
Immediately after deep anesthesia, the damaged spinal cord
(2.5 mm either side of the lesion) was removed at days 4 or 14
post-SCI and stored immediately at 280C in liquid nitrogen.
Western blotting was performed as described in Supporting
Information Methods. Images for immunoblot analysis were cap-
tured on an Image Quant LAS 4000 mini chemiluminescence
imaging analyzer (GE Healthcare Life Science, Piscataway, NJ;
http://www3.gehealthcare.com/) and the band intensity was
quantiﬁed using Image Quant TL software (GE Healthcare Life
Science). The intensity of each band was expressed relative to
that of b-actin. Kaleidoscope Prestained Standards (Bio-Rad Lab-
oratories, Hercules, CA) were used as molecular weight controls.
Statistical Analysis
All values are expressed as mean6 SD. Differences between
groups were examined for statistical signiﬁcance using one-
way factorial analysis of variance. A p< 0.05 denoted the
presence of signiﬁcant difference with Tukey’s posthoc analy-
sis. The above tests were conducted using SPSS software ver-
sion 11.0 (SPSS, Chicago, IL).
RESULTS
Relationship Between Survival Rate of Transplanted
BMSCs and Time of Transplantation
There was a decrease in the presence of GFP-positive trans-
planted BMSCs with time after transplantation such that by
28 days post BMSC transplant very few viable BMSCs were
observed. However, the number of surviving BMSCs that had
been transplanted at 1 or 3 days after SCI were markedly
greater than the number of surviving BMSCs that were trans-
planted at 7 or 14 days after SCI, with the greatest survived
number seen when BMSCs were transplanted at 3 days (Sup-
porting Information Fig. 2).
Early transplantation of BMSCs After SCI Increases
Locomotor Function and Decreases Pain
Hypersensitivity to Mechanical and Thermal
Stimulation
The effects of BMSC transplants were examined at the acute,
sub-acute and chronic stages after SCI (days 1, 3, 7 and 14).
This was to examine whether effects of the transplants on
pain hypersensitivity may be time dependent, and potentially
related to inﬂammatory reactions.
After BMSC transplantation at 14 days post-SCI, there
were no signiﬁcant effects in behavioral or sensory test out-
comes. In contrast, the mice that were treated with BMSCs at
3 days post-SCI showed the greatest improvement in their
BMS locomotor scores compared with the control group,
which was signiﬁcantly increased by day 14 post-SCI and per-
sisted up to week 6 after injury (Fig. 1A). Furthermore, the
most marked improvements in mechanical and thermal sensi-
tivity scores were also seen in the 3 day BMSC-treated group
(Fig. 1B, 1C) (see also Supporting Information Fig. 3). Subse-
quent analyses were performed on 3 day BMSC-treated mice
versus control or sham-operated mice.
BMSC Transplantation Reduced PKC-c- and p-CREB Pro-
tein Levels Spinal Cord Dorsal Horn Neurons
To examine whether BMSC transplantation reduces localized
putative markers of hyperexcitability in neurons, we assessed
immunopositivity for PKC-c and p-CREB colocalized with the
neuronal marker, NeuN in the dorsal horn post-SCI. In the
control group, SCI caused an increase in PKC-c-positivity in
NeuN-labeled neurons in the dorsal horn of the spinal cord
around the injury site. In contrast, BMSC transplantation sig-
niﬁcantly suppressed the observed expression of PKC-c in
NeuN-labeled cells in these locations (Fig. 2A, 2B). The num-
ber of cells positive for both p-CREB and NeuN in the dorsal
horn post-SCI was also increased in the control group,
Figure 1. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation improved the locomotor BMS score and hypersensitiv-
ities to mechanical and thermal stimulation after SCI. (A): Signiﬁcant improvement in hind-limb motor function was noted in the BMSC
transplantation group compared with the control group from day 14 post-SCI. The control group and BMSC transplantation group dem-
onstrated similar increases in responsiveness to both stimuli from day 14 post-SCI (sham, n5 18; control, n5 36; BMSC, n5 36; *,
p< 0.05). Data shown are means6 SD. (B, C): SCI-induced hypersensitivities to mechanical and thermal stimulation improved in the
BMSC transplantation group from day 14 post-SCI (sham, n5 15; control, n5 30; BMSC, n5 30; *, p< 0.05). Data shown are
means6 SD. (A–C): One-way factorial analysis of variance. Abbreviations: BMS, Basso Mouse Scale; BMSC, bone marrow-derived mesen-
chymal stem cells; SCI, spinal cord injury.
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Figure 2. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation reduced PKC-c and p-CREB immunoreactivity in the dorsal
horn after SCI. (A–D): PKC-c was found primarily in a band of cells restricted to the inner portion of lamina II in the sham group. High-
magniﬁcation pictures taken from respective boxed area. (A): PKC-c immunoreactivity after SCI was increased within the spinal dorsal horn
around the site of the lesion at day 14 post-SCI. (B): In the BMSC transplantation group, the PKC-c-positive area was signiﬁcantly smaller
than the control group (n5 3 each; *, p< 0.05). (C, D): Western blotting samples from the BMSC transplantation group showed signiﬁ-
cantly lower protein levels of PKC-c (n5 3 each; *, p< 0.05). (E, F): Representative immunoﬂuorescent staining of axial sections showing
colocalization of p-CREB staining (red) with NeuN staining (green) around the injured spinal cord at day 14 post-SCI. Colocalization of p-
CREB and NeuN neurons in the dorsal horn was signiﬁcantly reduced in the BMSC transplantation group compared with the control group
(n5 3 each; *, p< 0.05). High-magniﬁcation pictures taken from respective boxed areas. (G, H): Western blotting samples from the BMSC
transplantation group showed signiﬁcantly lower protein levels of p-CREB (n5 3 each; *, p< 0.05). Data shown are means6 SD. Scale
bars5 100 lm in (A) and 50 lm in (E). (B, D, F, H): One-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived
mesenchymal stem cells; p-CREB, phosphocyclic AMP response element binding protein; PKC-c; protein kinase C-c; SCI, spinal cord injury.
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Figure 3. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation reduced the prevalence of p-p38 MAPK- and p-ERK1/2-
positive CD11b cells. (A, B, E, F): Representative sagittal and axial immunoﬂuorescent staining showing colocalization of p-p38 MAPK
and p-ERK1/2 with CD11b at day 14 post-SCI. The presence of p-p38 MAPK and p-ERK1/2 colocalized with CD11b immunolabeled cells
was reduced in the BMSC transplantation group, especially in the spinal dorsal horn. Representative sagittal and axial immunoﬂuores-
cent staining in sham group showed little colocalization of p-p38 MAPK and p-ERK1/2 with CD11b. Scale bars5 200 lm. (C, D, G, H):
Western blotting samples from the BMSC transplantation group showed signiﬁcantly lower protein levels of p-p38 MAPK and p-ERK1/2
compared with the control group. Each graph shows the relative band intensity normalized to that of b-actin (n5 3 each; *, p< 0.05).
Data shown are means6 SD. (B, D, F, H): One-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived mesenchy-
mal stem cells; ERK, extracellular signal-regulated kinase; MAPK; mitogen activated protein kinase; SCI, spinal cord injury.
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especially in the deeper lamina, whereas BMSC transplanta-
tion signiﬁcantly attenuated this increase in p-CREB in NeuN-
labeled cells (Fig. 2E, 2F). Immunoblot analysis of extracted
proteins from the lesion site following SCI conﬁrmed that the
protein levels of PKC-c and p-CREB were decreased in the
BMSC transplantation group compared with the control group
(Fig. 2C, 2D, 2G, 2H).
BMSC Transplantation Decreased the Upregulation of
p-p38 MAPK- or p-ERK1/2- in CD11b Positive Cells in
the Spinal Cord Dorsal Horn
We mapped the presence of the MAPK family, that is, p-p38
MAPK, p-ERK1/2, and p-JNK in the spinal cord after SCI.
Although the observed levels of p-p38 MAPK, p-ERK1/2, and
p-JNK were weak in the intact spinal cord (data not shown),
marked increases in p-p38 MAPK, p-ERK1/2, and p-JNK were
noted in all laminae within the spinal cord dorsal horn at day
14 post-SCI in the control group. The observed increase in
expression of p-p38 was robust and tightly colocalized with
cells that were positive for CD11b, but almost negligible with
NeuN and glial ﬁbrillary acidic protein (GFAP)-positive neurons
and astrocytes, respectively. Similarly, p-ERK1/2 colocalized
with CD11b positivity, and there was also some colocalization
of p-ERK1/2 with GFAP-labeled cells, but very little colocaliza-
tion with NeuN-positive cells. P-JNK positivity colocalized with
some GFAP-positive cells, but was also seen, although weakly,
with some NeuN and CD11b-positive cells (Supporting Infor-
mation Fig. 4).
We evaluated the effects of BMSC transplantation on p-
p38 MAPK- and p-ERK1/2 levels in CD11b positive cells by
examining tissue sections post-SCI following dual immunohis-
tochemical labelling for these markers and by immunoblotting
of extracted proteins. Axial sections were used for the evalua-
tion of MAPK activities in the injured spinal dorsal horn,
where a reduction in the number of dual-labeled cells, espe-
cially in the spinal dorsal horn, was seen in the mice that
received BMSC transplants compared with the control group.
In contrast, the levels of expression of p-p38 MAPK and p-
ERK1/2 did not change in sham-operated group (Fig. 3A, 3B,
3E, 3F). In addition, protein levels of p-p38 MAPK and p-
ERK1/2 were decreased in the BMSC transplantation group
compared with the control group (Fig. 3C, 3D, 3G, 3H).
BMSC Transplantation Inhibited the Recruitment of
CD11b and GFP-Positive Hematogenous Cells to the
Lesion after SCI
To determine whether BMSC transplantation affects the
recruitment of bone marrow-derived cells into the injured spi-
nal cord, the contusive SCI was reproduced in chimeric mice
wherein the hematogenous cells were GFP labeled. Immuno-
staining of mid-sagittal sections of the spinal cord post-SCI
revealed a transient increase in the numbers of CD11b posi-
tive cells that colocalized with GFP positive cells in the control
group and BMSC-treated group, both of which peaked at 14
days after injury. However, the distribution of cells that were
dual labeled for CD11b and GFP was localized more to the
lesion site in the BMSC transplantation group (Fig. 4). In con-
trast, CD11b positivity was weak and there was little evidence
of migration of GFP-positive cells into the spinal cord in the
sham-operated group. In addition, there were signiﬁcantly
fewer CD11b and GFP dual-labeled cells in the spinal cord at
days 14 and 28 post-SCI in the BMSC transplanted group com-
pared with the control group (Fig. 4D). In contrast, the num-
bers of CD11b-positive and GFP-negative cells in the spinal
cord tended to be higher in the BMSC transplanted group
than in the control group, although insigniﬁcantly (Fig. 4E).
BMSC Transplantation Suppressed the Activation of p-
p38 MAPK and p-ERK1/2 in Bone Marrow-derived
Macrophages and Resident Microglia After SCI, and
Prevented Recruitment of Hematogenous Macro-
phages into the Injured Spinal Cord
In control mice, SCI resulted in an observed increase in the
presence of cells that were dually labeled with p-p38 MAPK
and GFP- or p-ERK1/2 and GFP within the spinal cord dorsal
horn. In contrast, BMSC transplantation not only appeared to
prevent the recruitment of GFP-positive bone marrow-derived
cells into the spinal cord dorsal column but it also appeared
to decrease their coexpression of p-p38 MAPK and p-ERK1/2
(Supporting Information Fig. 5).
Flow cytometry conﬁrmed the observed effects of BMSC
transplantation in attenuating the inﬁltration of hematoge-
nous macrophages and inhibiting the activation of those
fewer cells that were recruited as well as the resident micro-
glia. The number of CD11b and GFP dual-labeled cells was sig-
niﬁcantly lower in the BMSC transplantation group compared
with the control group (Fig. 5A–5C). In the subpopulation of
cells that was GFPpositive/CD11bpositive/CD45positive/Gr-1negative
(i.e., hematogenous macrophages), the number (percentages)
of activated p-p38 MAPK and p-ERK1/2-positive cells were
27786 55 (97.6%) and 27926 45 (98.1%) in the control
group, and 9766 286 (65.6%) and 6866 153 (46.1%), respec-
tively, in the BMSC transplantation group; these represented
signiﬁcant differences (Fig. 5D–5G). In the subpopulation of
cells that were GFPnegative/CD11bpositive/CD45positive/Gr-1negative
(i.e., resident microglia), the number (percentages) of acti-
vated p-p38 MAPK and p-ERK1/2-positive cells were
91016 267 (96.5%) and 79506 329 (84.3%) in the control
group, and 19206 391 (58.2%) and 10236 478 (31.0%),
respectively, in the BMSC transplantation group; these also
represented signiﬁcant differences (Fig. 5H–5K).
The Effects of BMSC Transplantation on BSCB Function
The effects of BMSC transplantation on the BSCB were eval-
uated by examining the presence of albumin, which leaks into
the parenchyma after central nerve system injury and PDGFR-
a, which localize on perivascular astrocytic endfeet [49]. After
the initial injury, BMSC transplantation signiﬁcantly reduced
leakage of albumin into the injury site at day 7 post-SCI com-
pared with the control group, while at day 14 post-SCI only
minor leakage of albumin was identiﬁed in both groups (Fig.
6A, 6C). Similarly, a signiﬁcant reduction in PDGFR-a immuno-
reactivity at the lesion site was seen at day 7 post-SCI in the
BMSC transplantation group compared with the control
group, with a further reduction observed in both groups at
day 14 (Fig. 6B, 6D).
BMSC Transplantation Moderated the Cytokine Profile
at the Lesion Site After SCI
Finally, we measured protein levels of tumor necrosis factor a
(TNF-a) and interleukin (IL)26 (as proinﬂammatory cytokines),
matrix metallopeptidase 9 (MMP-9) (as a mediator of early
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secondary vascular pathogenesis), chemotactic cytokine ligand
(CCL) 2, CCL5, CXC chemokine (C-X-C motif) ligand 10
(CXCL10) (as macrophage recruiting factors), and granulocyte–
macrophage colony-stimulating factor (GM-CSF) (as a local
microglial stimulating factor) at day 4 post-SCI (i.e., day 1
after transplantation) by immunoblot analysis. BMSC trans-
plantation reduced the intensities of the bands for TNF-a, IL-
6, MMP-9, CCL2, CCL5, and CXCL10, but increased that of
GM-CSF, compared with the SCI control group (Fig. 7).
DISCUSSION
Transplantation of BMSCs after SCI has been shown consis-
tently to improve motor function following SCI [51, 52]; how-
ever, the effect of BMSC transplants on neuropathic pain or
pain hypersensitivity is less clear [9–12]. Understanding the
possible outcome and mechanisms of action of BMSC trans-
plantations in terms of pain is an important issue, especially
as BMSCs are being considered for clinical treatments of SCI.
This study demonstrated signiﬁcant improvements in motor
function as well as mechanical allodynia and thermal hyperal-
gesia in a contusion model of thoracic SCI as a result of
BMSC transplantation. The ﬁndings were most marked in SCI
animals that were transplanted with BMSCs at 3 days after
injury, with no signiﬁcant improvement seen when animals
were transplanted at 14 days post-SCI. Previously, we demon-
strated that the greatest survival of transplanted BMSCs was
also achieved when these cells were transplanted at day 3
post-SCI, compared with transplantation at days 1, 7, and 14
post-SCI; furthermore, we and others found that day 3 post-
SCI is the time point when the numbers of major inﬂamma-
tory cells are still increasing in the injury site [39, 53]. Based
on these previous ﬁnding, as well as the present results, we
Figure 4. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation reduced the prevalence of CD11b and GFP double-
positive cells. (A, B, C): The number of CD11b-positive cells were scored in equal areas of tissue in the BMSC transplanted group and
control group. The prevalence of these cells reached a peak value at day 14 post-SCI. A more focalized lesion with the centralized pres-
ence of CD11b and GFP double-positive cells was a common ﬁnding in the BMSC transplantation group, compared with a larger lesion
seen in the control group. High-magniﬁcation pictures taken from respective boxed area. There are a few CD11b and GFP-positive cells
in sham operated model. Scale bars5 200 lm. (D, E): BMSC transplantation tended to reduce the prevalence of CD11b and GFP
double-positive cells at the lesion site, and tended to increase the prevalence of CD11b-positive and GFP-negative cells, although insig-
niﬁcantly (n5 3, each; *, p< 0.05). Data shown are means6 SD. (D, E): one-way factorial analysis of variance. Abbreviations: BMSC,
bone marrow-derived mesenchymal stem cells; GFP, green ﬂuorescent protein; SCI, spinal cord injury.
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suggest that transplantation of BMSCs in the acute as opposed
to subacute phase after SCI will have beneﬁcial effects on post-
SCI chronic neuropathic pain, at least in the short-term, which
supports their early use in clinical treatments. Further research
into methods designed to enhance the survival of transplanted
BMSCs is warranted. We have demonstrated previously that
blocking IL-6 signaling enhances BMSC survival and immuno-
modulatory and neuroprotective outcomes following BMSC
transplantation [38]. Such a strategy may also prove beneﬁcial
to improve the effects of BMSC transplantation on neuropathic
pain. In addition, a better understanding of the mechanisms of
action of BMSCs in suppressing pain after SCI is essential to
their successful therapeutic application.
Activation of the MAPK signaling pathway in dorsal horn
neurons and glial cells contributes to the development and
maintenance of neuropathic pain, which promotes long-term
potentiation and central sensitization. MAPK signaling cas-
cades are indicated through phosphorylation and hence acti-
vation of ERK1/2, JNK, and p38 MAPK; this in turn can lead to
phosphorylation and activation of the transcription factor,
CREB [19]. Activated CREB regulates the NR1 subunit on the
NMDA channel [19] and is upregulated in spinothalamic tract
cells in association with the development of neuropathic pain
[54]. Phosphorylated PKC-c is another important intracellular
signaling protein found in a speciﬁc subset of excitatory inter-
neurons in the inner region of lamina II, which receive input
from myelinated, non-noxious afferents [55]. PKC-c has simi-
larly been associated with neuropathic pain behavior [56]. The
present results indicated that early BMSC transplantation sup-
pressed the activation of p38 MAPK and ERK1/2 in microglia
Figure 5. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation suppressed the presence of pain-related proteins in the
injured spinal cord: ﬂow cytometry analysis for the p-p38 MAPK and p-ERK1/2 signaling pathways. Representative histograms of ﬂow
cytometry at day 14 post-SCI for the control and BMSC transplantation groups after SCI are shown. (A–C): The number of CD11b and GFP
dual-labeled cells was lower in the BMSC transplantation group compared with the control group. Speciﬁcally, BMSC transplantation pre-
vented the migration of hematogenous cells into the injured spinal cord (n5 3 each; *, p< 0.05). (D–G): The number of activated p-p38
MAPK and p-ERK1/2-positive cells in the population of GFPpositive/CD11bpositive/CD45positive/Gr-1negative cells (hematogenous macrophages)
were lower in the BMSC transplantation group than in the control group (n5 3 each; *, p< 0.05). (H–K): The number of activated p-p38
MAPK and p-ERK1/2-positive cells in the population of GFPnegative/CD11bpositive/CD45positive/Gr-1negative cells (resident microglia) were also
lower in the BMSC transplantation group than the control group (n5 3 each; *, p< 0.05). Data shown are means6 SD. (C, F, G, J, K):
one-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived mesenchymal stem cells; ERK, extracellular signal-
regulated kinase; GFP, green ﬂuorescent protein; MAPK; mitogen activated protein kinase; SCI, spinal cord injury.
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Figure 6. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation reduced disruption of the BSCB after SCI. (A, B): Repre-
sentative immunoﬂuorescent staining around the site of SCI lesion showing the prevalence of albumin and PDGFR-a in the injured spinal
cord at days 4, 7, and 14 post-SCI. There was comparatively little evidence of albumin leakage and PDGFR-a expression in the sham group
(high-magniﬁcation images for PDGFR-a positivity were taken from the respective boxed areas). Scale bars5 200 lm. (C, D): The albumin-
and PDGFR-a-positive areas in the gray matter (dotted line) were signiﬁcantly smaller in the BMSC transplanted group compared with the
control group at day 7 post-SCI, but no signiﬁcant differences were found between these two groups at days 4 and 14 post-SCI (n5 3
each; *, p< 0.05). Data shown are means6 SD. (C, D): one-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived
mesenchymal stem cells; BSCB, blood-spinal cord barrier; PDGFR-a, platelet-derived growth factor receptor a; SCI, spinal cord injury.
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and macrophages as well as that of CREB and PKC-c in dorsal
horn neurons in and around the lesion. This demonstrates
that early BMSC transplants after SCI suppressed several pain
signaling pathways and raises the question as to how BMSCs
might bring about these effects.
Several studies using animal models of neural damage
showed that MSC, including BMSCs, inhibit microglial activa-
tion and inﬂammatory responses [9, 57, 58]. In vitro experi-
ments have demonstrated that MSC reduce the
proinﬂammatory potential of dendritic cells and natural killer
cells by inhibiting the production of inﬂammatory factors,
including TNF-a and interferon c (IFN-c) [59] and they also
inhibit the activation of microglial cells [23, 60]. We have
reported previously that BMSCs enhance neuroregeneration
through overexpression of neurotrophic factors as well as
through modulation of immune responses following SCI from
an inﬂammatory (M1) to an alternatively activated (M2) mac-
rophage phenotype. This was associated with downregulation
of T helper 1 (Th1)-type cytokines TNF-a and IFN-c and
increased levels of Th2-type cytokines IL-4 and IL-13 at the
site of injury [39, 52]. Hence, this and previous work has pro-
vided compelling evidence that early BMSC transplants after
SCI suppress pain signaling pathways and pain hypersensitivity
through their anti-inﬂammatory and immunomodulatory
activity.
The pathogenesis of neuropathic pain and central sensiti-
zation after peripheral nerve injury seems to involve spinal
cord microglia as well as macrophages derived from hematog-
enous monocytes [34. 35]. We used GFP-labeled bone marrow
chimeric mice in this study for a better understanding of the
relative roles of these different cell types in SCI. The preva-
lence of activated resident microglia and inﬁltrating macro-
phages increased after SCI especially at day 14 when the
most severe pain hypersensitivity was noted in the control
group (Figs. 4 and 5). BMSC transplantation decreased p-p38
MAPK and p-ERK1/2 positivity both in the resident microglia
(GFP-negative cells) and hematogenous macrophages (GFP-
positive cells), indicating that BMSCs suppressed the activa-
tion of both cell types (Fig. 5). Furthermore, BMSC transplan-
tation signiﬁcantly reduced the recruitment of CD11b- and
GFP-dual-labeled hematogenous macrophages at days 14 and
28 to the injury site (Fig, 4D). The decrease in hematogenous
macrophage inﬁltration into the injured spinal cord after
BMSC transplantation was associated with modiﬁcations in
the secreted proﬁle of inﬂammatory cytokines and chemo-
kines known to increase endothelial permeability and attract
Figure 7. Bone marrow-derived mesenchymal stem cell (BMSC) transplantation decreased protein levels of inﬂammatory cytokines and
macrophage recruiting chemokines, while increasing that of granulocyte–macrophage colony-stimulating factor (GM-CSF). Each graph
shows the relative band intensity of each protein normalized to that of b-actin. Western blotting showed signiﬁcantly lower protein lev-
els of TNF-a and IL-6 (inﬂammatory cytokines), MMP-9 (a mediator of early secondary vascular pathogenesis), and CCL2, CCL5, and
CCXL10 (all macrophage recruiting factors), and signiﬁcantly higher protein levels of GM-CSF (a microglial stimulating factor) in the
BMSC transplanted group compared with the control group at day 4 post-SCI (n5 3 each; *, p< 0.05). Data shown are means6 SD. (A–
C): One-way factorial analysis of variance. Abbreviations: BMSC, bone marrow-derived mesenchymal stem cells; CCL, chemotactic cyto-
kine ligand; CCXL10, chemokine (C–X–C motif) ligand 10; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-6, interleukin 6;
MMP-9, matrix metallopeptidase 9; SCI, spinal cord injury; TNF-a, tumor necrosis factor a.
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inﬂammatory cells to wound sites, that is, TNF-a, IL-6, MMP-9,
CCL2, CCL5, and CXCL10 [35, 61–63], as well as direct evi-
dence of a restored BSCB, as shown through decreased cavita-
tion in the lesion site, reduced staining for albumin, and
evidence of tight junctions in the astrocytic endfeet and endo-
thelial cells following PDGFR-a immunolocalization and elec-
tron microscopy at day 7 after SCI (Fig 6) [49, 64]. Of these
changes, it is noteworthy that CCL2, a member of the chemo-
kines family that has been recently identiﬁed as a possible
key integrator of neuropathic pain in peripheral nerve injury
and SCI [35] was downregulated following BMSC transplanta-
tion in our study. In contrast to the recruitment of hematoge-
nous macrophages after SCI, proliferation of resident
microglia is mainly regulated by colony-stimulating factors
[65]. GM-CSF also facilitates axonal regeneration and func-
tional recovery after SCI [31]. The local increase in GM-CSF at
the injury level observed in our study could have stimulated
the proliferation of microglia, which tended to increase the
proportion of CD11b-positive and GFP-negative activated spi-
nal cord microglia at the lesion site, although insigniﬁcantly
(Fig. 4E).
CONCLUSION
In this study, we have demonstrated that early BMSC trans-
plants not only decreased the activation of MAPK signaling in
injured spinal cord but also altered the localized presence of
inﬂammatory mediators, which will have contributed to a
decrease BSCB disruption and reduction in the recruitment of
harmful blood-borne macrophages. The net effect of these
changes is likely to play a major role in reducing pain hyper-
sensitivity in the BMSC treated SCI animals.
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